News & Media

Boehringer Ingelheim News, Press Releases & Information

Quick access to the latest company news, including corporate, research & development and human pharmaceuticals for members of the media.

Press Release Subscription

Please submit the form below to receive press releases via email.

Information for...

PRESS RELEASE 06 Aug 2018 at 02:30

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Read more on Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
- Press Release
PRESS RELEASE 19 Jul 2018 at 08:00

Boehringer Ingelheim and Lilly announce Tradjenta’s CARMELINA^{^®} cardiovascular outcome trial meets primary endpoint

Read more on
Boehringer Ingelheim and Lilly announce Tradjenta’s CARMELINA^{^®} cardiovascular outcome trial meets primary endpoint
PRESS RELEASE 25 Jun 2018 at 08:00

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Read more on Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
PRESS RELEASE 23 Jun 2018 at 10:00

Jardiance^{^®} reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Read more on
Jardiance^{^®} reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
PRESS RELEASE 22 Jun 2018 at 08:00

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Read more on Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
- Press Release
PRESS RELEASE 31 May 2018 at 09:00

Real-world analysis reinforces that Gilotrif^{^®} dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

Read more on
Real-world analysis reinforces that Gilotrif^{^®} dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy
PRESS RELEASE 21 May 2018 at 14:00

Efficacy and safety of Ofev^{^®} (nintedanib) reinforced in new presentations at ATS 2018

Read more on
Efficacy and safety of Ofev^{^®} (nintedanib) reinforced in new presentations at ATS 2018
PRESS RELEASE 04 May 2018 at 08:00

Praxbind^{^®}, Specific Reversal Agent for Pradaxa^{^®}, Now Available in 3,200 Hospitals Nationwide

Read more on
Praxbind^{^®}, Specific Reversal Agent for Pradaxa^{^®}, Now Available in 3,200 Hospitals Nationwide
PRESS RELEASE 25 Apr 2018 at 08:30

Boehringer Ingelheim R&D pushes to transcend disease boundaries

Read more on Boehringer Ingelheim R&D pushes to transcend disease boundaries
- Press Release
PRESS RELEASE 25 Apr 2018 at 04:30

Boehringer Ingelheim has a very successful 2017 financial year

Read more on Boehringer Ingelheim has a very successful 2017 financial year
PRESS RELEASE 19 Apr 2018 at 09:00

Boehringer Ingelheim and HealthPrize Expand Successful Digital Patient Support Program

Read more on Boehringer Ingelheim and HealthPrize Expand Successful Digital Patient Support Program
PRESS RELEASE 17 Apr 2018 at 08:00

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

Read more on FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa
PRESS RELEASE 16 Apr 2018 at 08:00

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

Read more on Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease
- Press Release
PRESS RELEASE 04 Apr 2018 at 12:00

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Read more on Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
PRESS RELEASE 29 Mar 2018 at 08:00

New Large-Scale Trial Results Show Stiolto^{^®} Respimat^{^®} Prevents COPD Exacerbations Better Than Spiriva^{^®} Respimat^{^®}

Read more on
New Large-Scale Trial Results Show Stiolto^{^®} Respimat^{^®} Prevents COPD Exacerbations Better Than Spiriva^{^®} Respimat^{^®}
PRESS RELEASE 28 Mar 2018 at 08:00

Boehringer Ingelheim and Minor League Baseball Team Up to Raise Awareness of Rare Lung Disease - IPF

Read more on Boehringer Ingelheim and Minor League Baseball Team Up to Raise Awareness of Rare Lung Disease - IPF
PRESS RELEASE 19 Mar 2018 at 08:00

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Read more on FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
- Press Release
PRESS RELEASE 13 Mar 2018 at 09:00

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Read more on Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
PRESS RELEASE 09 Mar 2018 at 08:00

Boehringer Ingelheim to Present New Research on Pradaxa and Specific Reversal Agent Praxbind at American College of Cardiology Scientific Session

Read more on Boehringer Ingelheim to Present New Research on Pradaxa and Specific Reversal Agent Praxbind at American College of Cardiology Scientific Session
PRESS RELEASE 06 Mar 2018 at 08:00

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance^{^®} with new exercise capacity trials

Read more on
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance^{^®} with new exercise capacity trials

Search form

News & Media

Boehringer Ingelheim News, Press Releases & Information

Press Release Subscription